Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

@article{Havrdov2009EffectON,
  title={Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.},
  author={Eva Kubala Havrdov{\'a} and Steven L. Galetta and Michael Hutchinson and Dusan Stefoski and David Bates and Chris H. Polman and P. W. O'Connor and Gavin Giovannoni and J. Theodore Phillips and Fred D. Lublin and Amy L Pace and Richard U Kim and Robert Hyde},
  journal={The Lancet. Neurology},
  year={2009},
  volume={8 3},
  pages={254-60}
}
BACKGROUND The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study has prompted the investigation of whether natalizumab can increase the proportion of patients with relapsing-remitting multiple sclerosis who do not have disease activity. METHODS Post-hoc analyses of data from the AFFIRM study were done to determine the effects of natalizumab compared with placebo on the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS